KRAS T-cell receptor-transduced peripheral blood lymphocytes + TP53 T-cell receptor-transduced peripheral blood lymphocytes

KRAS T-cell receptor-transduced peripheral blood lymphocytes + TP53 T-cell receptor-transduced peripheral blood lymphocytes is an autologous cell therapy combination comprising T cells engineered to target two of the most prevalent driver mutations in oncology. Developed by the National Cancer Institute's Surgery Branch, this investigative treatment involves the ex vivo genetic modification of a patient’s own peripheral blood lymphocytes (PBLs) using viral vectors to introduce genes encoding specific T-cell receptors (TCRs). These TCRs are designed to recognize neoantigenic peptides derived from mutated KRAS (such as G12D or G12V variants) and mutated TP53 proteins when presented by the patient's specific human leukocyte antigen (HLA) molecules. Following a lymphodepleting chemotherapy regimen, the engineered T cells are re-infused into the patient, where they are intended to selectively identify and eliminate tumor cells harboring these intracellular driver mutations. This personalized immunotherapy approach is currently being evaluated in clinical trials for patients with refractory metastatic solid tumors, including colorectal, pancreatic, and lung cancers.

Other names

KRAS and TP53 TCR-engineered T-cellsKRAS and TP53 TCR-T cellsAutologous PBLs transduced with KRAS and TP53 TCRs